---
title: EFFECT of CHEWING GUM on CONTROLLING NAUSEA/VOMITING and THIRST in PATIENTS with ACUTE PANCREATITIS
nct_id: NCT06077188
overall_status: COMPLETED
phase: NA
sponsor: TC Erciyes University
study_type: INTERVENTIONAL
primary_condition: Acute Pancreatitis
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06077188.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06077188"
ct_last_update_post_date: 2025-03-03
last_seen_at: "2026-05-12T07:01:22.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# EFFECT of CHEWING GUM on CONTROLLING NAUSEA/VOMITING and THIRST in PATIENTS with ACUTE PANCREATITIS

**Official Title:** Erciyes University

**NCT ID:** [NCT06077188](https://clinicaltrials.gov/study/NCT06077188)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** TC Erciyes University
- **Conditions:** Acute Pancreatitis, Thirst
- **Start Date:** 2024-03-15
- **Completion Date:** 2024-06-29
- **CT.gov Last Update:** 2025-03-03

## Brief Summary

Nausea and vomiting are one of the most common symptoms in acute pancreatitis. In addition to pharmacological methods for nausea and vomiting, non-pharmacological methods can also be used. Among these, anticipatory nausea and vomiting can be prevented by behaviors aimed at distracting attention. This study will be conducted to evaluate the effect of chewing gum on the severity of nausea-vomiting and thirst in patients with acute pancreatitis. The study will be conducted with a total of 60 patients, 30 intervention and 30 control.

Patients in the intervention group will chew xylitol gum five times a day for three days. The patients' thirst and nausea and vomiting conditions will be examined.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Those diagnosed with acute pancreatitis,

  * Without total dental prosthesis,
  * Without salivary gland infection,
  * Those who have not had salivary gland surgery,
  * No difficulty in chewing,
  * Not receiving oxygen therapy,
  * Able to answer all questions and be communicativ

Exclusion Criteria:

* Those with diabetes,
* Does not like chewing gum,
* Receiving radiotherapy or chemotherapy,
```

## Arms

- **intervention group** (EXPERIMENTAL)
- **Control group** (NO_INTERVENTION)

## Interventions

- **Gum group** (OTHER) — Group chewing gum with xylitol

## Primary Outcomes

- **Thirst Severity -Visual Analog Scale** _(time frame: Apply in the morning of the 1st day after application)_ — Visual Analog Scale is a 10 cm long scale that evaluates the severity of thirst.

## Secondary Outcomes

- **Rhodes Nausea, Vomiting and Retching Index** _(time frame: Apply in the morning of the 1st day after application)_
- **Rhodes Nausea, Vomiting and Retching Index (** _(time frame: Apply in the morning of the 1st day after application)_

## Locations (1)

- Erciyes University Hospital, Kayseri, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.erciyes university hospital|kayseri||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06077188.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06077188*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*